Marie Thibault
Stock Analyst at BTIG
(3.82)
# 543
Out of 4,814 analysts
72
Total ratings
51.47%
Success rate
7.39%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $12 | $2.83 | +324.03% | 1 | Mar 20, 2025 | |
| EMBC Embecta | Upgrades: Buy | $26 | $11.13 | +133.60% | 2 | Nov 27, 2024 | |
| PODD Insulet | Maintains: Buy | $260 → $270 | $246.95 | +9.33% | 4 | Nov 8, 2024 | |
| MASI Masimo | Maintains: Buy | $166 → $170 | $152.40 | +11.55% | 3 | Oct 14, 2024 | |
| ESTA Establishment Labs Holdings | Maintains: Buy | $62 → $65 | $31.58 | +105.83% | 8 | Oct 14, 2024 | |
| BSX Boston Scientific | Maintains: Buy | $84 → $93 | $95.25 | -2.36% | 7 | Oct 14, 2024 | |
| HAE Haemonetics | Initiates: Buy | $112 | $58.23 | +92.36% | 1 | Sep 10, 2024 | |
| ATRC AtriCure | Maintains: Buy | $58 → $53 | $31.65 | +67.46% | 4 | Jul 31, 2024 | |
| DXCM DexCom | Maintains: Buy | $156 → $120 | $68.61 | +74.90% | 7 | Jul 26, 2024 | |
| XAIR Beyond Air | Downgrades: Neutral | n/a | $0.24 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.84 | - | 3 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $20 | $11.60 | +72.49% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $140 | $100.96 | +38.67% | 7 | Jun 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $3.23 | -7.12% | 3 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $125 | $129.70 | -3.62% | 11 | Jan 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $7 | $1.50 | +368.23% | 1 | Jun 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.77 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.61 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $130.88 | -95.42% | 1 | Apr 9, 2020 |
Orchestra BioMed Holdings
Mar 20, 2025
Initiates: Buy
Price Target: $12
Current: $2.83
Upside: +324.03%
Embecta
Nov 27, 2024
Upgrades: Buy
Price Target: $26
Current: $11.13
Upside: +133.60%
Insulet
Nov 8, 2024
Maintains: Buy
Price Target: $260 → $270
Current: $246.95
Upside: +9.33%
Masimo
Oct 14, 2024
Maintains: Buy
Price Target: $166 → $170
Current: $152.40
Upside: +11.55%
Establishment Labs Holdings
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $31.58
Upside: +105.83%
Boston Scientific
Oct 14, 2024
Maintains: Buy
Price Target: $84 → $93
Current: $95.25
Upside: -2.36%
Haemonetics
Sep 10, 2024
Initiates: Buy
Price Target: $112
Current: $58.23
Upside: +92.36%
AtriCure
Jul 31, 2024
Maintains: Buy
Price Target: $58 → $53
Current: $31.65
Upside: +67.46%
DexCom
Jul 26, 2024
Maintains: Buy
Price Target: $156 → $120
Current: $68.61
Upside: +74.90%
Beyond Air
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.24
Upside: -
Oct 6, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.84
Upside: -
Aug 16, 2023
Maintains: Buy
Price Target: $19 → $20
Current: $11.60
Upside: +72.49%
Jun 8, 2023
Maintains: Buy
Price Target: $165 → $140
Current: $100.96
Upside: +38.67%
Mar 29, 2023
Maintains: Buy
Price Target: $4 → $3
Current: $3.23
Upside: -7.12%
Jan 26, 2023
Maintains: Buy
Price Target: $120 → $125
Current: $129.70
Upside: -3.62%
Jun 24, 2022
Maintains: Buy
Price Target: $9 → $7
Current: $1.50
Upside: +368.23%
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.77
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $0.61
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $130.88
Upside: -95.42%